Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE: Relacorilant in Cushing Syndrome
NCT03697109Phase 3Completed
- Sponsor
- Corcept Therapeutics
- Start
- Nov 2018
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 11
01
Overview
A Phase 3 trial of relacorilant in Endogenous Cushing syndrome, sponsored by Corcept Therapeutics. Started Nov 2018; status: completed.
02
Drugs
relacorilant
03
Conditions
Endogenous Cushing syndrome
Beyond the preview
Go deeper on NCT03697109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697109.